Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Covid entities : Adamis pharmaceuticals corporation save search
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19DSMB met to evaluate interim clinical and safety data and clears Phase 2/3 study to continue
Published: 2022-03-14 (Crawled : 13:30) - biospace.com/
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: 0.52%
H: 0.0%
C: 0.0%
covid-19 treatment phase 2 als phase 2/3 covid
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
Published: 2022-03-14 (Crawled : 12:30) - globenewswire.com
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: 0.52%
H: 0.0%
C: 0.0%
covid-19 treatment als covid
Adamis Pharmaceuticals’ Clinical Study Assessing Tempol for the Treatment of COVID-19 Surpasses Enrollment Expectations
Published: 2022-02-28 (Crawled : 13:30) - biospace.com/
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: 1.62%
H: 3.23%
C: 1.6%
covid-19 treatment als covid enroll
Adamis Pharmaceuticals Provides Enrollment Update of Subjects in Phase 2/3 Study of Tempol for the Treatment of COVID-19
Published: 2022-02-07 (Crawled : 14:30) - globenewswire.com
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: 3.3%
H: 3.21%
C: 2.43%
covid-19 treatment phase 2 als phase 2/3 covid enroll
Adamis Pharmaceuticals Doses First Patients in Phase 2/3 Clinical Trial for Tempol in the Treatment of COVID-19
Published: 2021-09-02 (Crawled : 12:00) - globenewswire.com
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: 4.5%
H: 0.86%
C: -1.72%
covid treatment phase 2 phase 2/3 trial
Adamis Pharmaceuticals Announces a Publication with the Human Immune Monitoring Center at Stanford Demonstrating Tempol Significantly Inhibited Multiple Cytokines from COVID-19 Patient’s Cells
Published: 2021-08-24 (Crawled : 12:00) - biospace.com/
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: 1.83%
H: 5.41%
C: 1.8%
covid ford
Adamis Highlights National Institutes of Health (NIH) Article Entitled, “Tempol: A Potential Home Treatment for COVID-19”
Published: 2021-08-19 (Crawled : 16:00) - globenewswire.com
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: 3.86%
H: 8.55%
C: -1.83%
covid treatment potential
Adamis Highlights National Institutes of Health (NIH) Article Entitled, “Tempol: A Potential Home Treatment for COVID-19”NIH Researchers Contend that Tempol can be taken orally and may stop the replication of the virus that causes COVID-19
Published: 2021-08-19 (Crawled : 12:00) - biospace.com/
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: 3.86%
H: 8.55%
C: -1.83%
covid treatment potential research
Adamis Sends Letter to Stockholders Regarding Its Strategic Focus on Tempol as a Potentially Potent Treatment for COVID-19
Published: 2021-06-28 (Crawled : 12:00) - biospace.com/
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: 0.81%
H: 3.23%
C: -3.23%
covid treatment potential
Adamis Provides Update on Clinical Trial Start-Up Progress for Tempol in the Treatment of COVID-19Activities Proceeding for Phase 2/3 Trial Examining the Effects of Tempol for the Treatment of COVID-19
Published: 2021-06-11 (Crawled : 13:00) - biospace.com/
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: 3.92%
H: 2.83%
C: -5.66%
covid treatment phase 2 phase 2/3 trial
Adamis Provides Update on Clinical Trial Start-Up Progress for Tempol in the Treatment of COVID-19
Published: 2021-06-11 (Crawled : 12:00) - globenewswire.com
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: 3.92%
H: 2.83%
C: -5.66%
covid treatment trial
Adamis Highlights National Institute of Health Study Identifying Tempol as a Potential Antiviral Drug for COVID-19
Published: 2021-06-07 (Crawled : 12:00) - globenewswire.com
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: 10.0%
H: 9.09%
C: -4.55%
covid potential antiviral drug
Adamis Pharmaceuticals Provides Business UpdateNDA for ZIMHI™ submitted to the FDA; Phase 2/3 clinical trial preparation initiated for Tempol for treatment of COVID-19
Published: 2021-06-01 (Crawled : 13:00) - biospace.com/
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: 0.54%
H: 3.87%
C: 1.01%
covid treatment fda phase 2 phase 2/3 trial initiated
Adamis Pharmaceuticals Announces Tempol Reduces Lung Inflammation in the COVID-19 Challenged Hamster Model
Published: 2021-03-15 (Crawled : 14:00) - biospace.com/
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: 12.5%
H: 0.85%
C: -3.42%
covid covid-19
Adamis Pharmaceuticals Cleared to Proceed with Human Studies of Tempol for the Treatment of COVID-19
Published: 2021-02-22 (Crawled : 14:03) - globenewswire.com
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: 11.59%
H: 2.07%
C: -12.34%
covid treatment covid-19
Adamis Pharmaceuticals and Human Immune Monitoring Center at Stanford University Announce Preliminary Tempol Data in Cells from COVID-19 Patients
Published: 2021-01-28 (Crawled : 14:03) - globenewswire.com
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: 3.78%
H: 14.2%
C: -0.07%
covid ford
Adamis Pharmaceuticals Announces IND Submission to FDA for Tempol for the Treatment of COVID-19
Published: 2021-01-20 (Crawled : 14:04) - globenewswire.com
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: 27.7%
H: 61.48%
C: 39.11%
covid fda submission treatment covid-19
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.